达格列净对DECLARE-TIMI 58研究中白蛋白尿的影响
DECLARE-TIMI 58试验随机分配17,160例2型糖尿病患者接受达格列净或安慰剂,其中16,843例有基线尿白蛋白/肌酐比值(UACR)数据。达格列净组UACR从基线至4.0年的改善优于安慰剂组,且持续确认的UACR改善≥1个类别更常见(HR 1.45, 95%CI 1.35-1.56, P<0.0001)。达格列净还减少了UACR≥30 mg/g亚组的心肾复合结局和所有UACR亚组的肾脏特异性结局。
要点
- 达格列净改善所有基线UACR类别(包括正常白蛋白尿)患者的UACR。
- 达格列净组UACR持续改善≥1个类别的风险比安慰剂组高45%。
- 达格列净减少UACR≥30 mg/g患者的心肾复合结局和所有患者的肾脏特异性结局。
核心结论
- 达格列净对UACR和肾脏特异性结局在各基线UACR类别中均显示有利影响,包括正常白蛋白排泄患者。
- 结果提示SGLT2抑制剂可能用于糖尿病肾病的初级预防。
研究设计与样本
- DECLARE-TIMI 58是一项心血管结局试验,随机分配17,160例2型糖尿病、肌酐清除率>60 mL/min且伴动脉粥样硬化性心血管疾病(40.6%)或心血管疾病风险因素(59.4%)的患者至达格列净或安慰剂组。
- UACR在基线、6个月、12个月及之后每年检测,中位随访4.0年。
主要发现
- 基线UACR≤15 mg/g者9,067例(53.83%),>15至<30 mg/g者2,577例(15.30%),30-300 mg/g者4,030例(23.93%),>300 mg/g者1,169例(6.94%)。
- 以连续变量衡量,达格列净组从基线至4.0年UACR改善优于安慰剂组,所有UACR和eGFR类别均P<0.0001。
- 持续确认的UACR改善≥1个类别在达格列净组更常见(HR 1.45, 95%CI 1.35-1.56, P<0.0001)。
- UACR≥30 mg/g亚组中心肾复合结局风险降低(P<0.0125,交互P=0.033)。
- 所有UACR亚组中肾脏特异性结局均降低(P<0.05,交互P=0.480)。
临床怎么用
- 对于2型糖尿病伴心血管疾病或风险因素的患者,达格列净可改善白蛋白尿,包括正常白蛋白尿者。
- 达格列净可能有助于糖尿病肾病的初级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial, which included populations with lower cardiorenal risk. RESEARCH DESIGN AND METHODS: DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes, creatinine clearance >60 mL/min, and either atherosclerotic cardiovascular disease (CVD; 40.6%) or risk-factors for CVD (59.4%) to dapagliflozin or placebo. Urinary albumin-to-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and yearly thereafter. The change in UACR over time was measured as a continuous and categorical variable (≤15, >15 to <30, ≥30 to ≤300, and >300 mg/g) by treatment arm. The composite cardiorenal outcome was a ≥40% sustained decline in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m2, end-stage kidney disease, and cardiovascular or renal death; specific renal outcome included all except cardiovascular death. RESULTS: Baseline UACR was available for 16,843 (98.15%) participants: 9,067 (53.83%) with ≤15 mg/g, 2,577 (15.30%) with >15 to <30 mg/g, 4,030 (23.93%) with 30-300 mg/g, and 1,169 (6.94%) with >300 mg/g. Measured as a continuous variable, UACR improved from baseline to 4.0 years with dapagliflozin, compared with placebo, across all UACR and eGFR categories (all P < 0.0001). Sustained confirmed ≥1 category improvement in UACR was more common in dapagliflozin versus placebo (hazard ratio 1.45 [95% CI 1.35-1.56], P < 0.0001). Cardiorenal outcome was reduced with dapagliflozin for subgroups of UACR ≥30 mg/g (P < 0.0125, P interaction = 0.033), and the renal-specific outcome was reduced for all UACR subgroups (P < 0.05, P interaction = 0.480). CONCLUSIONS: In DECLARE-TIMI 58, dapagliflozin demonstrated a favorable effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. The results suggest a role for SGLT2i also in the primary prevention of diabetic kidney disease.
引用
- Mosenzon O, Wiviott SD, Heerspink HJL, et al. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021. PMID: 34233928. doi:10.2337/dc21-0076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。